BeyondSpring (BYSI) Common Equity (2015 - 2026)
BeyondSpring's (BYSI) quarterly Common Equity came in at -$36.0 million in Q2 2026, down 105.33% year-over-year from $676.0 million in Q2 2025, and down 18.68% quarter-over-quarter from -$30.4 million in Q1 2026.
Analysis
BeyondSpring (BYSI) Common Equity (2015 - 2026) Analysis & Trends
BeyondSpring has disclosed Common Equity across 12 years of filings, most recently posting -$36.0 million for Q2 2026.
- In Q2 2026, Common Equity fell 105.33% year-over-year to -$36.0 million; the TTM figure through Jun 2026 stood at -$36.0 million (down 105.33% YoY), while the FY2025 annual figure was -$32.2 million, down 125.14% from the prior year.
- Common Equity came in at -$36.0 million for Q2 2026 at BeyondSpring, down from -$30.4 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $500.0 million in Q3 2025 to a low of -$38.5 million in Q2 2024.
- Average Common Equity over 5 years is $14.4 million, with a median of -$21.9 million recorded in 2023.
- Year-over-year, Common Equity sank 422.66% in 2023 and surged 4639.26% in 2025.
- Over 5 years, Common Equity stood at -$14.1 million in 2022, then sank by 150.94% to -$35.3 million in 2023, then surged by 59.57% to -$14.3 million in 2024, then sank by 125.14% to -$32.2 million in 2025, then slipped by 12.01% to -$36.0 million in 2026.
- Per Business Quant data, the three most recent Common Equity figures were -$36.0 million in Q2 2026, -$30.4 million in Q1 2026, and -$32.2 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.14 Bn | 620.38 Bn | 17.26 Bn | 84.97 Bn |
| 2 | AbbVie | 451.04 Bn | 444.47 Bn | 12.70 Bn | -5.94 Bn |
| 3 | Merck | 357.43 Bn | 350.29 Bn | 12.21 Bn | 106.07 Bn |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn | 41.95 Bn |
| 5 | Pfizer | 157.52 Bn | 145.82 Bn | 10.94 Bn | 85.49 Bn |
| 6 | Sanofi | 52.14 Bn | 44.76 Bn | 10.79 Bn | 80.86 Bn |
| 7 | Revolution Medicines | 42.88 Bn | 42.88 Bn | - | 2.61 Bn |
| 8 | Incyte | 24.70 Bn | 20.16 Bn | 1.57 Bn | 6.34 Bn |
| 9 | United Therapeutics | 21.47 Bn | 18.80 Bn | 683.80 Mn | 6.40 Bn |
| 10 | BeyondSpring | 31.51 Mn | 31.51 Mn | - | -36.03 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -36.03 Mn |
| Mar 31, 2026 | -30.35 Mn |
| Dec 31, 2025 | -32.16 Mn |
| Sep 30, 2025 | 500.00 Mn |
| Jun 30, 2025 | -17.55 Mn |
| Mar 31, 2025 | -12.67 Mn |
| Dec 31, 2024 | -14.29 Mn |
| Sep 30, 2024 | -11.02 Mn |
| Jun 30, 2024 | -38.55 Mn |
| Mar 31, 2024 | -38.17 Mn |
| Dec 31, 2023 | -35.34 Mn |
| Jun 30, 2023 | -26.16 Mn |
| Dec 31, 2022 | -14.08 Mn |
| Jun 30, 2022 | 8.11 Mn |
| Dec 31, 2021 | 20.92 Mn |
| Sep 30, 2021 | 38.33 Mn |
| Jun 30, 2021 | 55.31 Mn |
| Mar 31, 2021 | 72.51 Mn |
| Dec 31, 2020 | 86.63 Mn |
| Sep 30, 2020 | 22.92 Mn |